Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb 5;185(2):127-34.
doi: 10.1503/cmaj.120138. Epub 2012 Oct 29.

Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment

Daniel L Jacoby  1 , Eugene C DePasquale, William J McKenna
Affiliations
Review

Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment

Daniel L Jacoby et al. CMAJ. .
No abstract available

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Management of hypertrophic cardiomyopathy. Brackets indicate third-line therapy with, at best, borderline evidence to support their use. Note: ACE = angiotensin-converting-enzyme inhibitor, ARB = angiotensin receptor blocker, ICD = implantable cardioverter defibrillator, LVOT = left ventricular outflow tract.
Figure 2:
Figure 2:
Risk stratification algorithm for prevention of sudden cardiac death. *Risk factors include cardiac arrest,, spontaneous sustained ventricular tachycardia,, family history of premature sudden cardiac death, unexplained syncope, left ventricular thickness of 3 or more cm, abnormal blood pressure response to exercise and nonsustained ventricular tachycardia (≥ 3 beats, at least 120 beats/min). Possible risk factors include LVOT obstruction (≥ 50 mm Hg at rest), contrast cardiac magnetic resonance imaging with extensive delayed enhancement, and high-risk mutation. Note: ECG = electrocardiogram, LVOT = left ventricular outflow tract.
See this image and copyright information in PMC

References

    1. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the cardia study. Coronary artery risk development in (young) adults. Circulation 1995;92:785–9 - PubMed
    1. Jarcho JA, McKenna W, Pare JA, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989;321:1372–8 - PubMed
    1. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006; 114:216–25 - PubMed
    1. Marian AJ. Phenotypic plasticity of sarcomeric protein mutations. J Am Coll Cardiol 2007;49:2427–9 - PMC - PubMed
    1. Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J 2011;32:1161–70 - PubMed

MeSH terms